Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients by Antithrombotic, Trialists et al.
Papers
Collaborative meta›analysis of randomised trials of
antiplatelet therapy for prevention of death, myocardial
infarction, and stroke in high risk patients
Antithrombotic Trialists’ Collaboration
Abstract
Objective To determine the effects of antiplatelet
therapy among patients at high risk of occlusive
vascular events.
Design Collaborative meta›analyses (systematic
overviews).
Inclusion criteria Randomised trials of an
antiplatelet regimen versus control or of one
antiplatelet regimen versus another in high risk
patients (with acute or previous vascular disease or
some other predisposing condition) from which
results were available before September 1997. Trials
had to use a method of randomisation that precluded
prior knowledge of the next treatment to be allocated
and comparisons had to be unconfounded—that is,
have study groups that differed only in terms of
antiplatelet regimen.
Studies reviewed 287 studies involving 135 000
patients in comparisons of antiplatelet therapy versus
control and 77 000 in comparisons of different
antiplatelet regimens.
Main outcome measure “Serious vascular event”:
non›fatal myocardial infarction, non›fatal stroke, or
vascular death.
Results Overall, among these high risk patients,
allocation to antiplatelet therapy reduced the
combined outcome of any serious vascular event by
about one quarter; non›fatal myocardial infarction
was reduced by one third, non›fatal stroke by one
quarter, and vascular mortality by one sixth (with no
apparent adverse effect on other deaths). Absolute
reductions in the risk of having a serious vascular
event were 36 (SE 5) per 1000 treated for two years
among patients with previous myocardial infarction;
38 (5) per 1000 patients treated for one month
among patients with acute myocardial infarction;
36 (6) per 1000 treated for two years among those
with previous stroke or transient ischaemic attack; 9
(3) per 1000 treated for three weeks among those with
acute stroke; and 22 (3) per 1000 treated for two years
among other high risk patients (with separately
significant results for those with stable angina
(P = 0.0005), peripheral arterial disease (P = 0.004),
and atrial fibrillation (P = 0.01)). In each of these high
risk categories, the absolute benefits substantially
outweighed the absolute risks of major extracranial
bleeding. Aspirin was the most widely studied
antiplatelet drug, with doses of 75›150 mg daily at
least as effective as higher daily doses. The effects of
doses lower than 75 mg daily were less certain.
Clopidogrel reduced serious vascular events by 10%
(4%) compared with aspirin, which was similar to the
12% (7%) reduction observed with its analogue
ticlopidine. Addition of dipyridamole to aspirin
produced no significant further reduction in vascular
events compared with aspirin alone. Among patients
at high risk of immediate coronary occlusion, short
term addition of an intravenous glycoprotein IIb/IIIa
antagonist to aspirin prevented a further 20 (4)
vascular events per 1000 (P < 0.0001) but caused 23
major (but rarely fatal) extracranial bleeds per 1000.
Conclusions Aspirin (or another oral antiplatelet
drug) is protective in most types of patient at
increased risk of occlusive vascular events, including
those with an acute myocardial infarction or
ischaemic stroke, unstable or stable angina, previous
myocardial infarction, stroke or cerebral ischaemia,
peripheral arterial disease, or atrial fibrillation. Low
dose aspirin (75›150 mg daily) is an effective
antiplatelet regimen for long term use, but in acute
settings an initial loading dose of at least 150 mg
aspirin may be required. Adding a second antiplatelet
drug to aspirin may produce additional benefits in
some clinical circumstances, but more research into
this strategy is needed.
Introduction
Previous meta›analyses of randomised trials have
shown that antiplatelet therapy prevents serious vascu›
lar events,1 arterial occlusion,2 and venous thrombo›
embolism3 among a wide range of patients at high risk
of occlusive vascular events. The proportional reduc›
tion in serious vascular events (non›fatal myocardial
infarction, non›fatal stroke, or death from a vascular
cause) was about one quarter in a wide range of high
risk patients, irrespective of why the risk was high and
irrespective of age, sex, blood pressure, or history of
diabetes.1
The previous meta›analyses, however, left some
important clinical questions unanswered. For instance,
although long term antiplatelet therapy was shown to
be of substantial benefit after ischaemic stroke, it was
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not known whether antiplatelet drugs were of net
benefit as an immediate treatment in the acute phase
of such strokes.4 There was also some uncertainty
about whether antiplatelet therapy was of net benefit in
patients with chronic conditions such as atrial
fibrillation, stable angina, and atherosclerotic periph›
eral arterial disease that had been less extensively stud›
ied. Daily doses of at least 75 mg of aspirin had been
shown to be effective in long term use, but theoretical
advantages had been proposed for lower doses.5
The previous meta›analyses included only those
trials that were available in 1990, and since then there
have been many additional trials of aspirin at various
doses and of other antiplatelet drugs.6 7 There have also
been trials of the effects of adding to aspirin another
antiplatelet drug with a different mechanism of action.
In addition, although certain anticoagulant regimens
were known to be effective for particular high risk
patients in the absence of antiplatelet therapy, it was
not known whether the addition of anticoagulants to
antiplatelets would provide additional protection. We
have therefore updated previous meta›analyses to
include studies available by September 1997. This
paper summarises the updated results from the trials
of antiplatelet drugs among high risk patients.
Methods
The methods and definitions used in the present meta›
analysis were broadly similar to those used in the pre›
vious meta›analysis.1
Identification of trials
Details of each trial included in the analysis are
available on bmj.com. The aim was to identify all trials,
published or otherwise, that were available by Septem›
ber 1997 and that compared an antiplatelet regimen
with a control or one antiplatelet regimen with another
among patients considered to be at high annual risk
(for example, over 3% a year) of vascular events
because of evidence of pre›existing disease (previous
occlusive event or predisposing condition). We
included only those trials that were believed to have
used a randomisation method that precluded prior
knowledge of the next treatment to be allocated (thus,
alternation or odd or even dates would not suffice) and
were “unconfounded”—that is, contained two ran›
domised groups that differed only with respect to the
antiplatelet comparison of interest. Trials of oral
antiplatelet regimens were eligible only if they had
assessed more than one day of treatment, but we
included trials of parenteral antiplatelet regimens of
any duration. An antiplatelet drug was defined as one
whose primary effect on the vascular system is to
inhibit platelet adhesion, platelet aggregation, or both.1
We identified relevant trials by searching several
electronic databases (Medline, Embase, Derwent,
Scisearch, and Biosis; search strategy available on
request); searching the trials registers of the Cochrane
Stroke and Peripheral Vascular Disease Groups;
manual searching of journals, abstracts, and proceed›
ings of meetings; scrutinising the reference lists of trials
and review articles; and inquiry among many
colleagues, including representatives of pharmaceuti›
cal companies.
Definition of outcomes
The primary measure of outcome was a “serious
vascular event” (that is, non›fatal myocardial infarction,
non›fatal stroke, or death from a vascular cause and
including any death from an unknown cause because
most deaths in high risk patients are likely to be due to
vascular causes). In order to allow the number of seri›
ous vascular events to be derived by adding the
numbers of non›fatal myocardial infarctions, non›fatal
strokes, and vascular deaths, we considered an event
non›fatal only if the patient survived to the end of the
scheduled follow up period (or died of a definitely
non›vascular cause). Each contributing trialist’s defini›
tion of a particular outcome (such as myocardial
infarction) was used for counting vascular events, and
we included all events classified by the trialist as prob›
able or definite.
Deaths were divided into those with a vascular
cause (defined as cardiac, cerebrovascular, venous
thromboembolic, haemorrhagic, other vascular, or
unknown cause) and those that were considered
definitely non›vascular. Strokes were subdivided into
intracranial haemorrhages (including intracerebral,
subdural, subarachnoid, and extradural haemorrhages)
and strokes of ischaemic or unknown aetiology;
transient ischaemic attacks were not to be included.
Major extracranial bleeds were those occurring outside
the cranial cavity that were considered by the trialist to
be serious (which, in general, meant that the patient
required admission to hospital or blood transfusion). If
during the trial a patient experienced more than one
type of non›fatal outcome—for example, a myocardial
infarction followed by a stroke—both events were
recorded, but such patients contributed only once to
the composite outcome of serious vascular event. If
during the trial a patient experienced more than one
non›fatal event of the same type (for example, two
myocardial infarctions) or more than one pathological
type of stroke (for example, a haemorrhagic stroke and
an ischaemic stroke), only the first was to be recorded.
Data requested
We asked the coordinators of all potentially eligible
trials for details about method of randomisation, blind›
ing of treatment allocation, scheduled duration of
treatment, and, if different, scheduled duration of
follow up. Investigators for trials that had randomised
at least 200 patients were asked to contribute, for each
patient originally randomised, data on baseline charac›
teristics (age, sex, blood pressure, and medical history)
and dates of randomisation, follow up, and any vascular
events that had occurred. In addition, we asked them
for a tabular summary of the numbers of patients
originally allocated to each treatment group (that is,
without any post›randomisation exclusions) and the
numbers of patients experiencing particular outcomes
during the scheduled follow up period. These
outcomes were non›fatal myocardial infarction, non›
fatal stroke (haemorrhagic or other), non›fatal or fatal
pulmonary embolism, death from a vascular or
unknown cause, death from a definitely non›vascular
cause, and major extracranial bleeding. Investigators
responsible for trials that had randomised fewer than
200 patients were asked only for the tabular summary
of the numbers of patients and outcomes (although a
few such studies did contribute individual patient data).
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In trials assessing a month or more of treatment, we
intended that analyses would be of events occurring
during the scheduled treatment period, but in two
trials follow up data were available only for a period in
excess of the scheduled treatment period (see bmj.com
for details).8 9 In trials with shorter courses of
treatment, we analysed events during a period as close
as possible to one month after randomisation. We
checked data both for internal consistency and for
consistency with relevant published reports and
referred queries back to trial coordinators. Especially
when data on individual patients were provided, the
calculated numbers of vascular events may differ
slightly from those reported in trial publications. Occa›
sionally, when trial data had been discarded by investi›
gators or were otherwise not available, the numbers of
vascular events could be determined only from
published reports.
Statistical methods
Proportional and absolute effects of treatment
We stratified analyses by trial to avoid direct
comparisons between individuals in different studies.
We calculated the observed minus the expected
number of events, and its variance, from standard 2×2
tables of outcome by treatment. These were then
summed over trials to give the grand total for observed
minus expected events (O-E) and its variance (V). We
then based significance tests on comparison of
z = (O-E)/’V with the standard normal distribution;
P denotes the two sided significance level and P > 0.05
is non›significant by convention. The typical odds ratio
for these trials was calculated by the one step method10
from b = (O-E)/V, either as exp(b) or, for rare events,
as (2 + b)/(2-b). For odds ratios between 0.5 and 2
these two methods give almost identical answers.
Some trials used a deliberately unequal random›
isation ratio and so had a substantial imbalance in the
numbers of patients in treatment and control groups.
We multiplied the control group in such trials by an
appropriate integer1 when calculating “adjusted”
control totals (although not when making other calcu›
lations). When comparing the percentages affected in
the treatment and in the adjusted control groups, we
calculated the standard error (SE) of the difference (D)
between these percentages as D/z.
Effects in specific categories of trials
We compared different trials or groups of trials using
standard ÷2 tests for heterogeneity or, where appropri›
ate, tests for trend between the observed effects on
vascular events (with appropriate allowance made for
multiple comparisons). But, even where there is
significant heterogeneity, groups of patients in whom
treatment is particularly advantageous or relatively inef›
fective can be difficult to identify reliably. Especially
when small numbers of patients in a particular category
have been studied, it is important that “lack of evidence
of benefit” when that category is considered on its own is
not misinterpreted as “evidence of lack of benefit.”11 As
antiplatelet therapy reduces vascular events in a wide
range of patients at high risk of occlusive vascular
disease, the relevant question in any particular category
is whether there is convincing evidence that there is no
material benefit from treatment.12 13
Description of trials
We identified 448 apparently randomised trials compar›
ing an antiplatelet regimen with a control or one
antiplatelet regimen with another among high risk
patients. After review and, in cases of doubt, consultation
with trial coordinators, 166 trials were excluded: 52 were
not properly randomised, 24 were confounded, three
had large numbers lost to follow up, 13 were abandoned
before any outcome data were collected, 20 had a cross›
over design, and 54 had not systematically recorded any
of the relevant outcome events. In addition, since the
focus of the present analyses was on patients at high risk
of occlusive arterial disease, we excluded trials among
patients with dementia or occluded retinal veins (even if
they had been included in the 1994 meta›analysis1).
Insufficient information was available from 19 eligible
trials among 3427 patients.
Details of the remaining 197 randomised trials that
compared antiplatelet therapy versus control (195 with
data on vascular events) and the 90 that compared dif›
ferent antiplatelet regimens (89 with data on vascular
events) are available on bmj.com. Information on indi›
vidual patients was available for trials that collectively
included 59% of the vascular events, and in these trials
fewer than 2% of patients were lost to follow up.
(Further details of excluded trials and missing data are
available on request.)
Results
Effects on serious vascular events among high risk
patients
Information about serious vascular events (non›fatal
myocardial infarction, non›fatal stroke, or vascular
death) was available from 195 trials of antiplatelet
treatment versus control among a total of 135 640
patients at high risk of occlusive arterial disease (com›
pared with 142 among 68 814 previously1). There was
substantial additional information about patients with
a history of stroke or transient ischaemic attack, those
treated early after an acute stroke, and those with stable
angina, atrial fibrillation, peripheral arterial disease, or
diabetes (table 1).
Overall, 7705 (10.7%) serious vascular events were
recorded among 71 912 high risk patients allocated
antiplatelet therapy versus an adjusted total of 9502
(13.2%) among 72 139 allocated control (P < 0.0001:
fig 1). When we subdivided the trials into five main
Table 1 Major changes in availability of data between previous and current
meta›analyses
No of patients No of vascular events
Previous Current Previous Current
Antiplatelet therapy v control:
Previous stroke/transient ischaemic attack 10 255 18 270 2062 3530
Acute stroke 29 40 821 5 3528
Stable angina 551 2 920 69 352
Atrial fibrillation 1 792 2 770 195 466
Peripheral arterial disease 4 939 9 214 486 605
Diabetes 1 200 4 961 55 820
Particular regimens:
Aspirin <75 mg v control 357 3 655 45 670
Aspirin <75 mg v aspirin >75 mg 56 3 570 7 488
Clopidogrel v aspirin 0 19 185 0 2033
Aspirin + dipyridamole v aspirin 5 317 10 404 628 1262
Aspirin + glycoprotein IIb/IIIa antagonist v aspirin 0 24 802 0 2733
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categories of high risk patient, there was clear evidence
that the proportional reductions in serious vascular
events differed among them (÷2 for heterogeneity
between these categories = 21.4, df = 4; P = 0.0003),
mainly because of the somewhat smaller effect observed
in patients treated during acute stroke (÷2 for heterogen›
eity between acute stroke and other categories = 18.0,
df = 1; P = 0.00002). Even so, the net benefit was highly
significant both among patients with acute stroke
(P = 0.0009) and, separately, among patients in each of
the other high risk categories (each P < 0.0001).
Among patients with acute stroke, the absolute
reduction in the risk of a serious vascular event was 9
(SE 3) per 1000 patients allocated antiplatelet therapy.
This is smaller than the absolute benefit of 22 to 38
fewer vascular events per 1000 among the other four
categories of high risk patients (fig 2). However, the net
benefit in patients with acute stroke was achieved with
less than one month of treatment, whereas the benefit
among patients with a previous stroke or transient
ischaemic attack (36 fewer events per 1000) resulted
from an average of 29 months of treatment. Thus, the
net benefit per month of antiplatelet treatment is sub›
stantially greater in the first month (starting at the time
of the acute stroke) than it is during long term
treatment for secondary prevention of stroke. Among
patients with high risk conditions other than acute
stroke, antiplatelet treatment produced a 25% (SE 2%)
proportional reduction in serious vascular events that
was similar in each of the four subcategories studied
(÷2 = 3.4, df = 3; NS, fig 1).
Effects on different measures of outcome among
high risk patients
Non›fatal myocardial infarction as outcome
Information was available on 2774 non›fatal myo›
cardial infarctions after randomisation in 159 trials
among high risk patients (compared with 2199 in 120
trials previously1) and on a further 4828 deaths attrib›
uted to coronary heart disease. Data for non›fatal
myocardial infarctions are in figures 3a›3c (but had
not been sought by the investigators in the main trials
among acute stroke patients). Overall, antiplatelet
treatment produced a 34% (3%) proportional reduc›
tion in non›fatal myocardial infarction (P < 0.0001; see
figure on bmj.com) and a 26% (2%) reduction in non›
fatal myocardial infarction or death from coronary
heart disease (P < 0.0001). In each of the four
categories of trial for which there was information, the
reduction in non›fatal myocardial infarction was highly
significant (each P < 0.001), although the proportional
reduction seemed to be greatest in patients treated
early after acute myocardial infarction (÷2 for
heterogeneity between subcategories = 12.3, df = 3;
P = 0.006). But, even among patients who had not had
an acute myocardial infarction, there was a clear reduc›
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Fig 1 Proportional effects of antiplatelet therapy on vascular events (myocardial infarction, stroke, or vascular death) in five main high risk
categories. Stratified ratio of odds of an event in treatment groups to that in control groups is plotted for each group of trials (black square)
along with its 99% confidence interval (horizontal line). Meta›analysis of results for all trials (and 95% confidence interval) is represented by
an open diamond. Adjusted control totals have been calculated after converting any unevenly randomised trials to even ones by counting
control groups more than once, but other statistical calculations are based on actual numbers from individual trials
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Fig 2 Absolute effects of antiplatelet therapy on vascular events (myocardial infarction,
stroke, or vascular death) in five main high risk categories. Adjusted control totals have been
calculated after converting any unevenly randomised trials to even ones by counting control
groups more than once
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tion of about one third in non›fatal myocardial infarc›
tion (31% (4%); P < 0.0001).
Stroke as outcome
Information was available on 3522 non›fatal strokes
after randomisation in 158 trials among high risk
patients (compared with 1496 in 122 trials previously1)
and on a further 1424 fatal strokes. Antiplatelet
therapy produced a 25% (3%) proportional reduction
in non›fatal stroke (P < 0.0001, see bmj.com and fig 3),
with no significant heterogeneity between the propor›
tional reductions in the five high risk categories of
patient (÷2 = 5.8, df = 4; NS). Among those trials that
recorded at least one haemorrhagic stroke, subdivision
of all strokes (fatal or not) according to aetiology indi›
cated that there was a proportional increase in fatal or
non›fatal haemorrhagic stroke of 22% (95% confi›
dence interval 3% to 44%; P < 0.01) and a proportional
decrease in fatal or non›fatal ischaemic stroke of
30% (24% to 35%; P < 0.0001), with no significant
heterogeneity between the proportional effects on
each of these types of stroke in the five high risk
categories studied (÷2 = 2.5 and 3.3 respectively; both
non›significant; table 2). But, although the propor›
tional changes in the incidence of haemorrhagic and
ischaemic stroke were about equal (and opposite) and
although the absolute risks and benefits of antiplatelet
therapy differed substantially from one category of
patient to another, in each category the absolute risks
were smaller than the benefits, so in each category of
patient the overall risk of stroke (including strokes of
unknown type) was reduced significantly (table 2).
Given these findings, the overall effect on total
stroke may be estimated in any specific category of
patient by considering the net absolute effects among
such patients of the combination of an increase of
about one quarter in the risk of haemorrhagic stroke
and of a decrease of about one quarter in the risk of
ischaemic stroke. So, for example, the proportional
reduction in total stroke incidence was only around
one half as large among patients with acute stroke as
among patients in other high risk categories (÷2 = 8.6,
df = 4; P = 0.07; table 2) because in the month after an
acute stroke about a quarter of the recurrent strokes in
the control group were attributed to haemorrhage (or,
particularly, to haemorrhagic transformation of the
original infarct) whereas in other circumstances only
about 6% were. Among all control patients (see totals
in table 2), the case fatality rate is higher for
haemorrhagic strokes (102 fatal, 160 not) than for
ischaemic strokes (361 fatal, 1493 not). This may
explain, at least in part, why the proportional effect of
antiplatelet therapy on fatal strokes (16% (7%)
reduction) seemed smaller, albeit non›significantly,
than the effect on non›fatal strokes (28% (4%)
reduction).
Vascular and non›vascular deaths
Information was available on 9605 deaths attributed to
vascular (or unknown) causes in 193 trials among high
risk patients (compared with 5253 in 141 trials
previously1). Antiplatelet therapy produced a highly
significant 15% (2%) proportional reduction in
vascular deaths (P < 0.0001; see bmj.com and fig 3),
with no significant heterogeneity between the propor›
tional reductions in each of the five high risk categories
of patient (÷2 = 7.8, df = 4; NS).
A further 1414 deaths were attributed to non›
vascular causes, but there was no excess of such deaths
(785/71 656 (1.1%) antiplatelet v 872/71 876 (1.2%)
adjusted control; odds ratio 0.92, 95% confidence
interval 0.82 to 1.03; NS). Hence, antiplatelet therapy
also produced a clear reduction of about one sixth in
all cause mortality (P < 0.0001; see bmj.com). If,
Table 2 Effects of antiplatelet therapy on fatal and non›fatal strokes, subdivided by stroke aetiology
Category of trial
No of fatal + No of non›fatal strokes/No of patients (combined %) Stratified odds ratio
(SE)
Adjusted absolute
difference per 1000 (SE)Antiplatelet groups Adjusted controls
Probable or definite haemorrhagic stroke (in trials with at least one haemorrhagic stroke)
Previous myocardial infarction 6+5/5476 (0.20) 6+8/5507 (0.25) 0.8 (0.4) −0.5 (0.9)
Acute myocardial infarction 6+0/8821 (0.07) 1+1/8830 (0.02) 3.0 (1.4) 0.05 (0.03)
Previous stroke/transient ischaemic attack 35+26/9553 (0.64) 26+28/9610 (0.56) 1.2 (0.3) 0.8 (1.0)
Acute stroke* 68+140/20223 (1.03) 60+109/20205 (0.84) 1.2 (0.1) 1.9 (0.9)
Other high risk 22+9/4498 (0.69) 9+14/4529 (0.51) 1.3 (0.3) 1.8 (2.0)
Total 137+180/48571 (0.65) 102+160/48681 (0.54) 1.22 (0.10)
÷2=2.5, df=4; NS
Probable or definite ischaemic stroke (in trials with at least one haemorrhagic stroke)
Previous myocardial infarction 17+40/5476 (1.04) 17+65/5507 (1.49) 0.69 (0.14) −4.5 (2.1)
Acute myocardial infarction 8+29/8821 (0.43) 14+51/8830 (0.75) 0.58 (0.15) −3.2 (1.1)
Previous stroke/transient ischaemic attack 106+662/9553 (8.04) 136+876/9610 (10.53) 0.75 (0.05) −24.0 (5.1)
Acute stroke 90+231/20223 (1.59) 125+335/20205 (2.28) 0.69 (0.06) −6.9 (1.4)
Other high risk 45+110/4498 (3.45) 69+166/4529 (5.19) 0.63 (0.09) −17.4 (4.0)
Total 266+1072/48571 (2.75) 361+1493/48681 (3.88) 0.70 (0.03)
÷2=3.3, df=4; NS
Strokes of any aetiology (in trials recording data on non›fatal strokes)
Previous myocardial infarction 33+83/9222 (1.26) 51+129/9250 (1.95) 0.64 (0.10) −6.9 (1.9)
Acute myocardial infarction 13+32/9300 (0.48) 19+54/9291 (0.58) 0.62 (0.15) −3.0 (1.2)
Previous stroke/transient ischaemic attack 288+957/11493 (10.83) 314+1248/11527 (13.55) 0.77 (0.04) −27.2 (5.1)
Acute stroke 275+432/20238 (3.49) 293+522/20220 (4.03) 0.89 (0.05) −5.4 (1.9)
Other high risk 131+257/16607 (2.34) 152+364/16733 (3.08) 0.73 (0.06) −7.5 (1.7)
Total 740+1761/66860 (3.74) 829+2317/67021 (4.75) 0.78 (0.03)
÷2=8.6, df=4; P=0.07
*Includes haemorrhagic transformation of original infarct.
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however, such antiplatelet therapy did have a
protective or adverse effect on some specific cause of
death (such as a particular type of cancer), the forego›
ing analysis of all non›vascular deaths might well be
too insensitive to detect this. Site specific data on
deaths from cancer were not available, so the
suggestions that aspirin might prevent intestinal
cancer14 or cause renal cancer15 could not be examined
directly.
Pulmonary embolism
Only 32 trials planning to record symptomatic pulmo›
nary embolism had recorded at least one non›fatal
event, and among them antiplatelet therapy signifi›
cantly reduced the risk of fatal or non›fatal pulmonary
embolism (150/32 777 (0.46%) antiplatelet v 200/
32 758 (0.61%) adjusted control; odds reduction 25%
(10%); P < 0.01). In both the treatment group and the
control group, about half of those who had a
pulmonary embolism survived to the end of the trial.
Hence, the risk reduction was about one quarter in
both cases (although with wide confidence intervals).
This proportional reduction is somewhat smaller than
that found in the 1994 meta›analysis of trials among
surgical and high risk medical patients (47/4716
(1.0%) v 129/4730 (2.7%); odds reduction 64%, 95%
confidence interval 50% to 73%; P < 0.0001)3 and in
the subsequent pulmonary embolism prevention trial
(55/8726 (0.6%) v 91/8718 (1.0%); odds reduction
43%, 18% to 60%; P = 0.002) among patients having
hip or knee surgery.16
Major extracranial bleeds
Information was available on 787 major extracranial
bleeds in 60 trials recording at least one such bleed.
These were generally defined as bleeds that were fatal
or required transfusion; among them, 159 (20%)
caused death. Little information was available on major
extracranial bleeds from the trials of long term
treatment after a myocardial infarction. Overall, the
proportional increase in risk of a major extracranial
bleed with antiplatelet therapy was about one half
(odds ratio 1.6, 1.4 to 1.8), with no significant difference
between the proportional increases observed in each
of the five high risk categories of patient (÷2 = 2.6,
df = 4; NS; table 3). The proportional increase in fatal
bleeds was not significantly different from that for non›
fatal bleeds, although only the excess of non›fatal
bleeds was significant. There were too few fatal and
non›fatal bleeds in any particular category to estimate
the absolute risks directly. However, a useful estimate of
the excess risk of a major extracranial bleed may be
obtained indirectly by applying the proportional
increase of about one half to the absolute risk of bleed›
ing in that category of patients.
Effects in different categories of high risk patients
Patients with history of myocardial infarction
Among 18 788 patients with a history of myocardial
infarction in 12 trials (compared with 18 573 such
patients in 11 trials previously1), allocation to a mean
duration of 27 months of antiplatelet therapy resulted
in 36 (SE 5) fewer serious vascular events per 1000
patients (fig 2). This benefit reflects large and highly
significant reductions in non›fatal reinfarction (18 (3)
fewer per 1000; P < 0.0001: fig 3a) and vascular death
(14 (4) fewer/1000; P = 0.0006) as well as a smaller, but
still significant, reduction in non›fatal›stroke (5 (1)
fewer/1000; P = 0.002). These benefits were substan›
tially larger than the excess risk of major extracranial
bleeding, which was estimated indirectly from table 3
(as described above) to be about three additional major
extracranial bleeds per 1000 patients allocated
antiplatelet therapy—that is, an excess of about 1 such
bleed per 1000 patients per year.
Patients with acute myocardial infarction
Data were available on 19 288 patients with suspected
acute myocardial infarction in 15 trials (compared with
18 773 such patients in nine trials previously1), nearly
all of whom were in the ISIS›2 trial.11 Allocation to a
mean duration of one month of antiplatelet therapy
resulted in 38 (5) fewer serious vascular events per
1000 treated patients (fig 2). This reflects large and
highly significant reductions in non›fatal reinfarction
(13 (2) fewer/1000; P < 0.0001: fig 3b) and in vascular
death (23 (4) fewer/1000; P < 0.0001), together with a
small but significant reduction in non›fatal stroke (2 (1)
fewer/1000; P = 0.02). The net benefit is substantially
larger than the excess risk of major extracranial bleed›
ing (for example, from arterial lines), which was
estimated to be about 1›2 additional major extracranial
bleeds per 1000 patients allocated antiplatelet therapy.
Patients with a history of stroke or transient ischaemic
attack
The amount of information available on the effects of
prolonged antiplatelet therapy among patients with a
history of stroke or transient ischaemic attack has
increased substantially since 1990 (table 1). This is
mainly because of the second European stroke preven›
Table 3 Effects of antiplatelet therapy on fatal and non›fatal major extracranial bleeds
Category of trial
No of fatal + No of non›fatal major bleeds/No of patients
(combined %)* Stratified odds ratio
(SE)
Adjusted absolute
excess risk/1000
(SE)Antiplatelet groups Adjusted controls†
Previous myocardial infarction 1+2/672 (0.45) 1+2/668 (0.45) — —
Acute myocardial infarction 2+26/9134 (0.31) 3+20/9136 (0.25) 1.2 (0.3) 0 (1)
Previous stroke/transient ischaemic attack 15+65/8276 (0.97) 7+32/8289 (0.47) 2.0 (0.3) 5 (2)‡
Acute stroke 60+135/20 195 (0.97) 43+73/20 178 (0.57) 1.7 (0.1) 4 (1)§
Other high risk 17+212/8881 (2.58) 17+135/8897 (1.71) 1.5 (0.1) 9 (3)‡
Total 95+440/47 158 (1.13) 71+262/47 168 (0.71) 1.6 (0.1)¶
*Only trials with systematic recording of all major extracranial bleeds (and that recorded at least one such bleed) are included.
†Percentage adjusted for unbalanced randomisation (see statistical methods).
‡P<0.001.
§P<0.0001.
¶÷2 for heterogeneity=2.6, df=4; NS.
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tion study, in which 6602 such patients were allocated
to receive aspirin (25 mg twice daily), modified release
dipyridamole (200 mg twice daily), both, or neither in a
2×2 factorial design.17 Overall, among 18 270 patients
in 21 trials (compared with 10 255 patients in 18 trials
previously1), allocation to a mean duration of 29
months of antiplatelet therapy resulted in 36 (6) fewer
serious vascular events per 1000 patients (fig 2). This
benefit reflects a large and highly significant reduction
in non›fatal stroke (25 (5) fewer/1000; P < 0.0001: fig
3c), along with a smaller but still significant reduction
in non›fatal myocardial infarction (6 (2) fewer/1000;
P = 0.0009).
Although the reduction in vascular mortality of 7
(4) per 1000 was only marginally significant (P = 0.04),
the highly significant reductions in non›fatal vascular
events and in all cause mortality (15 (5) fewer deaths/
1000; P = 0.002) strongly reinforce the conclusion that
prolonged antiplatelet therapy reduces the risk of
death in such patients. These benefits clearly exceeded
the estimated excess risk of bleeding of about 1›2 addi›
tional major extracranial bleeds per 1000 patients per
year.
Patients with acute ischaemic stroke
Almost no information about the effects of antiplatelet
therapy in acute ischaemic stroke was available for the
previous analyses (table 1).1 Subsequently, results have
emerged from the international stroke trial of 300 mg
daily aspirin versus open control18 and the Chinese
acute stroke trial of 160 mg daily aspirin versus
placebo.19 These trials each included about 20 000
patients with suspected acute ischaemic stroke.20 Overall,
among 40 821 such patients in seven trials, allocation to
a mean duration of three weeks of antiplatelet therapy
produced an 11% (3%) proportional reduction in vascu›
lar events (fig 1), which was somewhat smaller than in
other high risk categories. The resulting absolute reduc›
tion of 9 (3) fewer serious vascular event per 1000
patients (fig 2) reflects significant reductions in non›fatal
stroke (4 (2) fewer/1000; P = 0.003; fig 3d) and in vascu›
lar deaths (5 (2) fewer/1000; P = 0.05), with information
on non›fatal myocardial infarction not recorded in
either the international stroke trial or Chinese acute
stroke trial.
For 40 428 patients in four of these trials,18 19 21 22 it
was possible to separate the stroke outcomes into those
considered to be due to haemorrhage and those that
were considered to be ischaemic (or of unknown
cause). Antiplatelet therapy produced an absolute
excess of 1.9 (SE 1.0) haemorrhagic strokes per 1000
patients, which was counterbalanced by an absolute
reduction of 6.9 (1.4) fewer ischaemic strokes per 1000,
yielding the overall reduction in the risk of any further
stroke (including those of unknown cause) of 5.4 (1.9)
per 1000. The excess risk of major extracranial
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Fig 3 Absolute effects of antiplatelet therapy on various outcomes
in patients with (a) previous myocardial infarction (12 trials);
(b) acute myocardial infarction (15 trials); (c) previous stroke or
transient ischaemic attack (21 trials); and (d) acute (presumed
ischaemic) stroke (seven trials). Adjusted control totals have been
calculated after converting any unevenly randomised trials to even
ones by counting control groups more than once. In “any death”
columns, non›vascular deaths are represented by lower horizontal
lines (and may be calculated by subtracting vascular deaths from
any deaths)
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bleeding was estimated at about three additional such
bleeds per 1000 allocated antiplatelet therapy, and
more detailed analysis of the international stroke trial
suggested that much of this excess occurred when
antiplatelet therapy was given in conjunction with
heparin (absolute excess 9 (2) per 1000 with heparin v
2 (1) per 1000 without heparin).18
Effects in other high risk categories
In the previous cycle of analyses,1 information was
available on serious vascular events from 104 trials
among about 20 000 patients with various other
conditions associated with an increased risk of vascular
events. Subsequently, more information has become
available for certain of these conditions, which we have
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Fig 4 Proportional effects of antiplatelet therapy on vascular events in 195 trials in high risk patients subdivided by disease category. Stratified
ratio of odds of an event in treatment groups to that in control groups is plotted for each group of trials (black square) along with its 99%
confidence interval (horizontal line). Meta›analysis of results for each main category and for all trials (and 95% confidence interval) is
represented by an open diamond. Adjusted control totals have been calculated after converting any unevenly randomised trials to even ones by
counting control groups more than once, but other statistical calculations are based on actual numbers from individual trials
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grouped into four main categories: coronary artery
disease (which includes unstable angina, coronary
artery bypass grafting, coronary angioplasty, stable
angina, and heart failure); high risk of embolism
(which includes non›rheumatic atrial fibrillation,
cardiac valve disease, and cardiac valve surgery);
peripheral arterial disease (which includes intermittent
claudication, peripheral grafting, and peripheral
angioplasty); and other high risk conditions (which
includes haemodialysis patients having fistula or shunt
placement, diabetes mellitus, and carotid disease).
In patients in each of the four main categories and
their 14 components, the practical medical question is
whether to give antiplatelet therapy. For that, it may
suffice to know that the overall results for these “other
high risk” categories show substantial reductions in
myocardial infarction, stroke, and vascular death. This
general conclusion can then be applied semiquantita›
tively in each of the 14 separate components, even if
the results in one particular component considered
separately do not indicate significant benefit.
Many of the odds ratios for individual components
are associated with confidence intervals that are at
least as wide as the likely magnitude of any treatment
benefit (fig 4). Thus, even if antiplatelet therapy were of
similar efficacy in all circumstances, several false nega›
tive results would be expected just from the play of
chance. For example, the lack of evidence of benefit in
patients randomised because of diabetes is not good
evidence of lack of benefit in diabetic patients. (Indeed,
even without any allowance for multiple comparisons,
the 99% confidence interval for the proportional risk
reduction in diabetic patients includes a risk reduction
of one quarter, and the risks among diabetic patients
are so high that the absolute benefit from such a risk
reduction would be substantial.) Even if it is accepted,
however, that antiplatelet treatment will produce an
appreciable risk reduction in each type of patient at
high risk of occlusive vascular disease, it is still of some
interest to consider whether there is good evidence
that the proportional risk reductions are different in
different subcategories.
Other high risk patients with coronary artery disease
Overall, among 15 828 patients with coronary artery
disease in 55 trials (compared with 9731 patients in 35
such trials previously1) there was a highly significant
37% (5%) proportional reduction in serious vascular
events (P < 0.0001; fig 4). The substantial increase in
information available about the effects of antiplatelet
therapy among patients with stable angina is due
mainly to the results of the Swedish angina pectoris
aspirin trial, in which 2035 patients were allocated to
receive 75 mg aspirin daily or placebo.23 There were
independently significant benefits among patients with
unstable angina (46% (7%) reduction, P < 0.0001),
those having coronary angioplasty (53% (14%)
reduction, P < 0.0002), and those with stable angina
(33% (9%) reduction, P = 0.0004).
The proportional risk reduction among patients
who had recently had coronary artery bypass grafting
was smaller (4% (14%)), but the confidence interval is
wide and includes a risk reduction of one quarter.
Hence, the apparent lack of effect of antiplatelet
therapy on vascular events immediately after coronary
artery bypass surgery may—given the clear evidence of
benefit among other patients with coronary artery
disease—be largely or wholly due to chance. Only 134
patients have been included in trials of antiplatelet
therapy for heart failure, but most such patients have
coronary artery disease,24 for which antiplatelet
therapy is of known benefit.
Patients at high risk of embolism
Several cardiac and vascular conditions are associated
with an increased risk of embolism to the brain or per›
ipheral circulation, including atrial fibrillation (which
was predominantly non›rheumatic), cardiac valve
disease, and cardiac valve replacement. Overall, among
5162 patients at high risk of embolism in 14 trials
(compared with 3190 such patients in nine trials previ›
ously1) there was a highly significant 26% (7%) propor›
tional reduction in serious vascular events (P = 0.0003;
fig 4).
Atrial fibrillation is the commonest cardiac
condition giving rise to embolism and is an important
cause of stroke among elderly people.25 Most of the
additional information about the effects of antiplatelet
therapy among patients with atrial fibrillation was pro›
vided by the European atrial fibrillation trial,26 in which
high risk patients with a previous stroke or transient
ischaemic attack were randomised to aspirin or
placebo (or oral anticoagulant, if eligible). Overall,
among 2770 patients with atrial fibrillation in four
trials there was a proportional reduction of 24% (9%)
in serious vascular events (or 23% (10%) if one small
trial of indobufen v placebo that also included some
patients without atrial fibrillation is excluded27).
Patients with peripheral arterial disease
Overall, among 9214 patients with peripheral arterial
disease in 42 trials (compared with 4939 such patients in
33 trials previously1) there was a proportional reduction
of 23% (8%) in serious vascular events (P = 0.004; fig 4),
with similar benefits among patients with intermittent
claudication, those having peripheral grafting, and those
having peripheral angioplasty (heterogeneity test
÷2 = 3.8, df = 3; NS). Much of the new evidence came
from the atherosclerotic disease evolution by picota›
mide trial, in which 2304 patients with intermittent clau›
dication were allocated to receive the thromboxane
synthase inhibitor picotamide or placebo.6
Other high risk conditions
Other groups of patients at high risk of occlusive arterial
disease that have been studied include haemodialysis
patients having shunt or fistula replacement, patients
with diabetes, patients having carotid endarterectomy,
and patients with asymptomatic carotid stenosis. Studies
of antiplatelet therapy among haemodialysis patients
after placement of a dialysis shunt or fistula included in
the previous meta›analysis1 had typically lasted only a
few weeks, but several of the more recent trials assessed
the effects of 12›18 months of treatment. Overall, among
2632 patients in 14 trials (compared with only 525
patients in 10 trials previously1), antiplatelet therapy
produced a 41% (16%) proportional reduction in
serious vascular events. Even though this result is based
on only 99 vascular events among such patients, it is
consistent with the benefits seen in other circumstances.
Chronic renal failure is associated with impaired
haemostasis, but only 46 major extracranial bleeds (27/
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1333 (2.0%) antiplatelet v 31/1371 (2.3%) adjusted con›
trol; NS) were recorded in these trials, so the size of any
bleeding hazards cannot be reliably estimated.
Diabetes mellitus is also associated with an
increased risk of vascular events, even in the absence of
diagnosed cardiovascular disease. Much of the new
information comes from the early treatment diabetic
retinopathy study,28 in which 3711 people with diabetes
(and, generally, no history of myocardial infarction or
stroke) were allocated to receive 650 mg aspirin daily
or placebo. Overall, among 4961 patients with diabetes
in nine trials (compared with 1365 patients in seven
trials previously1), antiplatelet therapy was associated
with only a 7% (8%) proportional reduction in serious
vascular events (which remains consistent, however,
with the reduction of about one quarter observed
overall). None of the trials reported major extracranial
bleeds, but the early treatment diabetic retinopathy
study indicated that aspirin did not increase the risk of
vitreous or retinal haemorrhage.29
Relatively small numbers of patients with carotid
atherosclerosis have been studied. The overall results
in five trials of antiplatelet therapy after carotid endar›
terectomy and one among patients with asymptomatic
carotid disease (36/339 (10.6%) antiplatelet v 43/337
(12.8%) adjusted control; 19% (22%) reduction; NS) are
consistent with those observed in other patients at high
risk of stroke.
Comparisons of different antiplatelet regimens
Many small trials compared different antiplatelet
drugs, but the analysis in figure 5 is restricted to direct
randomised comparisons in which a total of at least
500 patients had been studied. The effects of different
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Fig 5 Direct comparisons of proportional effects of different antiplatelet regimens on vascular events in high risk patients. Only meta›analyses
involving a total of 500 or more high risk patients are shown. *Includes one trial comparing 1400 mg/day v 350 mg/day,30 and another
(excluding those with acute stroke) comparing 1000 mg/day v 300 mg/day among patients who were also given dipyridamole.31 †Includes two
trials comparing 75›325 mg aspirin daily v <75 mg aspirin daily32 33 and one trial of 500›1500 mg aspirin daily v <75 mg aspirin daily.34
‡Includes cilostazol, sulotroban, trapidil, E5510, eptifibatide, and GR32191B. Stratified ratio of odds of an event in regimen 1 group to that in
regimen 2 group is plotted for each group of trials (black square) along with its 99% confidence interval (horizontal line). Meta›analysis of
results for all trials for a particular comparison (and 95% confidence interval) is represented by an open diamond
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regimens can also be compared indirectly by compar›
ing the size of the protective effect observed in the trials
of one particular antiplatelet regimen versus control
with the size of the protective effect in trials of another
antiplatelet regimen versus control (fig 6). Such
indirect comparisons need to be interpreted more cau›
tiously than direct comparisons because there is some
potential for bias if patients in the trials had different
types of disease. Much of this bias can, however, be
avoided by restricting attention to proportional reduc›
tions among high risk patients other than those with
acute stroke (in whom antiplatelet therapy has a
significantly smaller proportional effect on serious vas›
cular events).
Effects of different doses of aspirin
Aspirin doses below 75 mg daily have been suggested
to be more effective than higher doses because such
low doses are reported to “spare” prostacyclin (a plate›
let antiaggregant and vasodilator) and cause less
gastrointestinal toxicity.5 Since the previous meta›
analysis, much more information has become available
from both direct and indirect comparisons on very low
daily aspirin doses (table 1). Overall, among 3570
patients in three trials directly comparing aspirin >75
mg daily v aspirin < 75 mg daily there was no
significant difference between the different aspirin
regimens (fig 5). However, aspirin doses of < 75 mg
have been less widely assessed than doses of 75›150
Category of trial
No of trials
with data
34
19
12
3
65
Observed-
expected
Odds ratio (CI)
-147.1
-219.9
-72.0
-18.9
-452.3
Variance
707.8
742.6
183.8
136.5
1717.0
% Odds
reduction
(SE)
19 (3)
26 (3)
32 (6)
13 (8)
23 (2)
16 (7)
16 (8)
32 (7)
24 (19)
38 (16)
45 (33)
50 (28)
47 (15)
24 (4)
0 0.5 1.0
Treatment effect P<0.0001
1.5 2.0
Antiplatelet : control
1621/11 215
(14.5)
1526/13 240
(11.5)
366/3370
(10.9)
No (%) of vascular events
1930/11 236
(17.2)
1963/13 273
(14.8)
517/3406
(15.2)
500-1500
160-325
75-150
<75
Other antiplatelet drugs:
Any other single agent
Aspirin + another antiplatelet drug:
15
19
42
6
4
4
2
9
101
-30.9
-23.8
-50.5
-5.6
-12.2
-3.2
-4.7
-16.1
-147.0
173.0
140.7
132.3
20.5
25.8
5.3
6.7
25.6
529.9
392/2696
(14.5)
315/2411
(13.1)
278/3435
(8.1)
47/364
(12.9)
41/1583
(2.6)
8/406
(2.0)
458/2734
(16.8)
361/2416
(14.9)
385/3475
(11.1)
59/367
(16.1)
66/1602
(4.1)
14/409
(3.4)
Sulfinpyrazone
Other†
Triflusal
Suloctidil
Dipyridamole
Picotamide
Sulotroban
Ticlopidine
10/314
(3.2)
41/647
(6.3)
1132/11 856
(9.5 )
19/309
(6.1)
73/641
(11.4)
1435/11 953
(12.0)
46
2
48
-172.6
-6.5
-179.1
488.7
18.5
507.2
1036/9703
(10.7)
38/283
(13.4)
1074/9986
(10.8)
1393/9738
(14.3)
50/278
(18.0)
1443/10 016
(14.4)
6035/51 494
(11.7)
7644/51 736
(14.8)
-715.7 2449.6188 25 (2)
Aspirin + dipyridamole
Aspirin alone (mg daily):
Aspirin + sulfinpyrazone
Any combination
All trials
316/1827
(17.3)
354/1828
(19.4)
Any aspirin* 3829/29 652
(12.9)
4764/29 743
(16.0)
30 (4)
30 (20)
30 (4)
Allocated
antiplatelet
Adjusted
control
Heterogeneity of odds reductions between:
  Different aspirin doses: c 2=7.7, df=3; P=0.05
  Other antiplatelet v any aspirin: c 2=10.8, df=8; P>0.1
Antiplatelet better Antiplatelet worse
Fig 6 Indirect comparisons of proportional effects of different antiplatelet regimens on vascular events in high risk patients (excluding those
with acute stroke). Only meta›analyses involving 500 or more high risk patients are shown. *Some trials contributed to more than one
comparison. †Includes indobufen, flurbiprofen, GR32191B, dazoxiben, and trapidil. Stratified ratio of odds of an event in treatment groups to
that in control groups is plotted for each group of trials (black square) along with its 99% confidence interval (horizontal line). Meta›analysis
of results for each main comparison and for all trials (and 95% confidence interval) is represented by an open diamond. Adjusted control totals
have been calculated after converting any unevenly randomised trials to even ones by counting control groups more than once, but statistical
calculations are based on actual numbers from individual trials
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mg daily, so there remains uncertainty about whether
such low doses are as effective as daily doses of >75
mg. Among the trials of higher daily doses of aspirin v
no aspirin (fig 6), no particular range of aspirin dose
was preferable for the prevention of serious vascular
events. The proportional reduction in vascular events
was 19% (3%) with 500›1500 mg daily, 26% (3%) with
160›325 mg daily, and 32% (6%) with 75›150 mg daily.
However, daily doses < 75 mg seemed to have a some›
what smaller effect (proportional reduction 13% (8%);
÷2 = 7.7, df = 3; P = 0.05; fig 6).
There was no good evidence to support the
suggestion that aspirin doses of>1000 mg daily might
be preferable for the prevention of serious vascular
events among patients at high risk of stroke.35 36 This
observation is reinforced by the aspirin and carotid
endarterectomy trial (which was not included in this
meta›analysis as it was reported after 1997). In that
study the risk of the composite outcome of myocardial
infarction, stroke, or death within three months of
carotid endarterectomy was significantly lower among
patients taking 81 mg or 325 mg aspirin daily than in
those taking 625›1300 mg.37
In trials comparing aspirin with control, the
proportional increase in the risk of a major
extracranial bleed was similar with all daily aspirin
doses < 325 mg (odds ratios 1.7 (95% confidence
interval 0.8 to 3.3) for < 75 mg; 1.5 (1.0 to 2.3) for
75›150 mg; and 1.4 (1.0 to 2.0) for 160›325 mg). Two
trials that compared 75›325 mg aspirin daily with < 75
mg daily also found no significant difference in major
extracranial bleeds (39/1576 (2.5%) with 75›325 mg v
28/1555 (1.8%) with < 75 mg; NS).
Effects of antiplatelet drugs other than aspirin
Overall, after trials among patients with acute stroke had
been excluded, 81 731 patients were included in 166
trials comparing a single antiplatelet drug with control
among high risk patients (compared with 73 218
patients in 141 trials previously1). Indirect comparisons
of the different antiplatelet drugs provided no clear evi›
dence of any differences in the effects on serious vascu›
lar events (÷2 for heterogeneity between any aspirin
regimen and the other antiplatelet drugs = 10.8, df = 8;
NS; fig 6), indicating that no large differences exist.
Direct randomised comparisons of different
antiplatelet regimens could, if they were large enough,
assess more reliably any modest differences that might
exist. Most direct comparisons have assessed the effects
of replacing aspirin with another antiplatelet (fig 5).
Large scale randomised evidence was available only for
clopidogrel versus aspirin.7 Overall, among 19 185
patients with a history of myocardial infarction, stroke,
or peripheral arterial disease, clopidogrel reduced
serious vascular events by 10% (4%) compared with
aspirin (970/9599 (10.1%) clopidogrel v 1063/9586
(11.1%) aspirin; P = 0.03). This is similar to the 12%
(7%) reduction observed in trials of ticlopidine (a thieno›
pyridine drug similar to clopidogrel) versus aspirin.
The clopidogrel versus aspirin in patients at risk of
ischaemic events trial also showed that the drug was
relatively safe.38 However, the true size of any difference
between clopidogrel and aspirin could not be reliably
estimated, since the 99% confidence interval ranged
from a negligible benefit to a 20% further reduction in
serious vascular events.
Effects of adding another antiplatelet drug to aspirin
Although the size of any difference between aspirin
and other antiplatelet drugs may only be small, the
addition to aspirin of an antiplatelet drug that acts
through a different pathway might provide more
substantial benefit than aspirin alone. The effects of
adding dipyridamole, sulfinpyrazone, ticlopidine, or
intravenous glycoprotein IIb/IIIa antagonists have
been tested in randomised trials (fig 5).
Overall, among 10 404 patients in 25 trials
comparing dipyridamole plus aspirin with aspirin
alone (compared with 5317 in 14 trials previously1), the
addition of dipyridamole to aspirin was associated with
only a non›significant further 6% (6%) reduction in
serious vascular events (614/5198 (11.8%) aspirin plus
dipyridamole v 648/5206 (12.4%) aspirin alone; fig 5).
This overall result includes 183 v 236 patients with
non›fatal stroke, 150 v 134 with non›fatal myocardial
infarction, and 286 v 279 vascular deaths (with 5 v 1
having both a non›fatal myocardial infarction and a
non›fatal stroke). The apparent reduction in non›fatal
stroke was derived mainly from one large study (109 v
158),17 but this result was not supported by the findings
for non›fatal stroke in the other studies (74 v 78) or by
the overall findings for non›fatal myocardial infarction
or for vascular death.
Experimental and clinical studies have indicated
that the platelet antiaggregatory effects of ticlopidine
and aspirin may be additive.39 The combination has
been studied among patients having coronary artery
stenting, although mainly in non›randomised com›
parisons and case series.40 Several randomised trials
have compared the combination of ticlopidine and
aspirin with the combination of an oral anticoagulant
and aspirin, but only two randomised trials have com›
pared ticlopidine plus aspirin versus aspirin, and only
one (the stent anticoagulation restenosis study41) was
unconfounded. In that study, the addition of ticlopi›
dine to aspirin was associated with a non›significant
21% (24%) further reduction in serious vascular events
(fig 5). There was, however, a non›significant increase in
major extracranial bleeds (15/546 (2.8%) ticlopidine
plus aspirin v 8/557 (1.4%) aspirin alone). Further evi›
dence that adding a thienopyridine to aspirin produces
additional benefit among patients at acute risk of
coronary occlusion has recently been provided by the
clopidogrel in unstable angina to prevent recurrent
events trial,42 but these results are not included as they
were reported after September 1997.
The final common pathway of platelet aggregation
is thought to be mediated by activation of platelet
glycoprotein IIb/IIIa receptors by a platelet agonist
(such as ADP, collagen, or thrombin) followed by
crosslinking of activated receptors by circulating
fibrinogen molecules.43 Drugs that block this receptor
might therefore be especially effective. Many such
drugs have now been developed, and in September
1997, 15 trials were available comparing aspirin plus a
short (12›96 hour) intravenous infusion of a glycopro›
tein IIb/IIIa antagonist with aspirin alone (one small
study had studied an oral drug). Overall, among 24 802
patients in these 15 trials, the addition of an
intravenous glycoprotein IIb/IIIa antagonist to aspirin
produced a highly significant 19% (4%) proportional
reduction in serious vascular events (P < 0.0001),
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corresponding to the avoidance of about 20 vascular
events per 1000 patients in just one month.
The proportional reduction in vascular events was
significantly larger among patients having percutane›
ous coronary intervention than among patients not
having such intervention (32% (6%) v 12% (5%);
heterogeneity test ÷2 = 8.7, df = 1; P = 0.003). However,
since patients with acute coronary syndromes not hav›
ing a coronary procedure were at high risk of vascular
events, addition of a glycoprotein IIb/IIIa antagonist
was still associated with a worthwhile absolute benefit
(15 vascular events avoided for 1000 treated during one
month P < 0.02). Overall, these benefits were offset by
an absolute excess of 23 major extracranial bleeds per
1000 patients treated, although fatal bleeding was rare.
The absolute risk of bleeding after percutaneous
coronary intervention may be minimised by early
removal of the sheath and reducing the dose of
heparin.44 There were few intracranial haemorrhages
(20/12 791 (0.2%) glycoprotein IIb/IIIa antagonist plus
aspirin v 13/12 833 (0.1%) adjusted aspirin alone; NS).
Discussion
Since the previous meta›analysis,1 large amounts of
information have become available from trials in
patients having coronary artery procedures and in
patients with acute stroke, stable angina, atrial
fibrillation, peripheral arterial disease, and diabetes
mellitus. Consequently, this analysis extends the direct
evidence of benefit from antiplatelet therapy to a much
wider range of patients at high risk of occlusive vascu›
lar disease. Antiplatelet therapy reduced the risk of
serious vascular events (non›fatal myocardial infarc›
tion, non›fatal stroke, or vascular death) by about one
quarter, not just among patients with unstable angina,
acute myocardial infarction, stroke, or transient ischae›
mic attacks1 but also among other patients with coron›
ary or peripheral arterial disease and those at high risk
of embolism. Overall mortality was also significantly
reduced in these high risk patients, and, compared with
these benefits, the absolute risk of fatal and major non›
fatal bleeds was small.
Generalisability of findings to types of patients not
studied directly
Because these proportional risk reductions in vascular
events were statistically reliable and seemed roughly
homogeneous over the wide range of settings studied
in these trials (fig 4) the protective effects of antiplatelet
therapy should be expected to apply to an even wider
range of high risk patients than those categories for
which the present meta›analysis provides direct
evidence of benefit. Thus, it would be inappropriate to
base conclusions about the effects of antiplatelet
therapy in each small subcategory of patients solely on
the results from that subcategory. Compare, for
example, the apparently contrasting effects on vascular
events among patients having coronary angioplasty (in
whom antiplatelet therapy seems to halve the risk) and
those having coronary artery bypass grafting (in whom
it seems to have no effect). Given the overall evidence
for a reduction in serious vascular events of about one
quarter among such a wide range of patients at high
risk of occlusive vascular disease, it would not be
reasonable to conclude that antiplatelet therapy halves
vascular events after angioplasty but has no protective
effect after coronary artery bypass surgery (particularly
when antiplatelet therapy has been shown to produce
a massively significant reduction in thrombotic
occlusion of bypass grafts2).
Similarly, although antiplatelet therapy was associ›
ated with only a non›significant 7% (8%) proportional
reduction in serious vascular events among patients
with diabetes mellitus (but, predominantly, no history
of myocardial infarction or stroke), these results do not
provide reliable evidence of a lack of worthwhile
benefit in such patients. Indeed, taken as a whole they
indicate the converse, although direct evidence from
further randomised trials of antiplatelet therapy
among diabetic patients would still be helpful.
However, our previous finding that antiplatelet therapy
is similarly effective among patients with pre›existing
symptomatic vascular disease who do and do not have
diabetes1 suggests that aspirin is likely to be effective for
the primary prevention of vascular events among
diabetic patients. Furthermore, there is now good
evidence that antiplatelet therapy is not associated with
any special risks (such as bleeding in the eye) in
patients with diabetes.29 Hence, it may be appropriate
to consider antiplatelet therapy in diabetic patients
who are at substantial risk of a first vascular event (such
as those with proteinuria)45 and non›diabetic patients
at high risk because of pre›existing vascular disease,
even if there is no direct evidence of benefit (as for
patients undergoing coronary artery surgery or those
with heart failure46), provided that there are no special
risks of bleeding that might outweigh the benefit. Thus,
these findings can reasonably be extrapolated to a far
wider range of high risk patients than those studied,
but the further the extrapolation goes, the more desir›
able it is to have direct evidence—for example, for
patients with renal disease, who are at high risk of
myocardial infarction and ischaemic stroke47 but who
also have special risks of bleeding.
Acute stroke
The randomised evidence that is available from about
40 000 patients with acute stroke shows that, although
antiplatelet therapy is associated with about two more
major extracranial bleeds per 1000 treated in the
absence of concomitant heparin,18 there will be about
four fewer patients with a non›fatal stroke and five
fewer patients dying from a vascular cause. Moreover,
even among acute stroke patients who did not have
computed tomography to exclude pre›existing cer›
ebral haemorrhage before starting treatment,
antiplatelet therapy seemed to produce net benefit.20
Hence, there is now good reason to consider starting
antiplatelet therapy as soon as possible after suspected
acute ischaemic stroke, preferably after confirmation
by computed tomography (unless this would result in
undue delay). This complements the previous evidence
that continuing antiplatelet therapy for some years
after the acute phase of ischaemic stroke produces
substantial further reductions in risk.1
Benefits of different antiplatelet regimens
The available data allow three main questions about
treatment regimens to be examined: which range of
aspirin doses seems most promising; is some other
antiplatelet drug better than aspirin; and does any
antiplatelet drug add to the net benefit of aspirin?
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Aspirin regimens
Within a few days of beginning 75 mg aspirin daily,
cyclo›oxygenase is virtually completely inhibited in
platelets, producing an antithrombotic effect.5 The
present analyses indicate that high doses of 500›1500
mg aspirin daily (which are more gastrotoxic48) are no
more effective than medium doses of 160›325 mg/day
or low doses of 75›150 mg/day (figs 5 and 6). Results
from trials of lower doses are less conclusive. Hence,
the available evidence supports daily doses of aspirin
in the range 75›150 mg for the long term prevention
of serious vascular events in high risk patients. In clini›
cal situations where an immediate antithrombotic
effect is required (such as acute myocardial infarction,
acute ischaemic stroke, unstable angina), a loading
dose of about 150›300 mg, which is sufficient to
produce rapid and complete inhibition of thrombox›
ane mediated platelet aggregation,49 should probably
be given.
Other antiplatelet drugs
Even though aspirin can prevent about one quarter of
serious vascular events in a wide range of high risk
patients, the residual risk may still be high. Hence,
antiplatelet regimens are needed that are more
effective than aspirin alone. Any real differences
between two antiplatelet drugs are likely to be smaller
than the differences between antiplatelet therapy and
no antiplatelet therapy, so reliable comparisons
between different drugs may require direct random›
isation of many thousands, or even tens of thousands,
of high risk patients. Such evidence exists only for
clopidogrel versus aspirin, and this indicates that clopi›
dogrel may be slightly more effective than aspirin (par›
ticularly when the evidence for ticlopidine, which is
similar in structure and mechanism of action to clopi›
dogrel, is also considered).50
Addition of other antiplatelet drugs to aspirin
Addition to aspirin of an antiplatelet drug that
prevents platelet aggregation through some other
pathway may well produce a further reduction in the
risk of serious vascular events. This has now been
shown for short term treatment. Large randomised
trials among patients having percutaneous coronary
interventions have found that adding a short
intravenous infusion of glycoprotein IIb/IIIa antago›
nist reduces the risk of early arterial or stent thrombo›
sis.43 In the present meta›analysis, evidence of benefit
was limited to a follow up of only around one month,
but recently published studies show that the benefit of
glycoprotein IIb/IIIa antagonists is maintained for at
least six months (and possibly longer).51–53 Despite this,
the oral IIb/IIIa›antagonists have not been found to
add to the effects of aspirin.54
Similarly, the addition of dipyridamole to aspirin
has not been shown clearly to produce additional
reductions in serious vascular events, although one
trial suggested that there may be a worthwhile further
reduction in stroke.17 Reasons for this apparent effect
on stroke in that study include the possibility that the
newer (and more bioavailable) formulation of dipyri›
damole was more effective than the older preparation.
It is also plausible that these findings (which were not
supported by other studies) arose largely or wholly by
the play of chance, or were due to an insufficient daily
aspirin dose or a slight antihypertensive effect of
dipyridamole. Dipyridamole is being tested further in
the European and Australian stroke prevention in
reversible ischaemia trial.55
Clopidogrel and ticlopidine, which are both
thienopyridines, act by blocking ADP dependent activa›
tion of platelets. The effects of their antiplatelet proper›
ties on occlusive vascular events could therefore be
complementary to those of aspirin, which inhibits
thromboxane dependent activation. A large trial that
assessed the effects of adding clopidogrel to aspirin
among patients with unstable angina recently reported
promising results,42 and the second Chinese cardiac
study is assessing this question among patients with
acute myocardial infarction.56 Long term studies of the
effects of adding clopidogrel to aspirin might also be
useful among other types of patients at high risk of
occlusive vascular disease. Such studies could also exam›
ine the important question of whether adding clopidog›
rel is effective in patients who were taking aspirin when
the event occurred (so called aspirin failures).
In the high risk setting of percutaneous coronary
intervention or among high risk patients with an acute
coronary syndrome, intensification of antiplatelet
therapy by adding an intravenous glycoprotein IIb/IIIa
antagonist or thienopyridine to aspirin may be appro›
priate. In other circumstances, however, aspirin at a
dose of 75›150 mg daily is likely to be an appropriate
antiplatelet regimen unless patients have a definite
contraindication to aspirin—for example, definite
allergy or appreciable gastric symptoms even with low
dose aspirin. Clopidogrel might be an appropriate
alternative in such patients.
Benefits exceed hazards in most high risk patients
Our results suggest that among individuals at high risk
of occlusive vascular disease, the proportional risk
reductions with antiplatelet therapy are roughly similar
in most categories of patient (although they are smaller
in acute stroke). Consequently, a patient’s absolute risk
is likely to be more important than the proportional
reduction in serious vascular events in determining the
likely benefit of antiplatelet therapy. In patients at par›
ticularly high risk of vascular events, the benefits of
antiplatelet therapy are large. For example, among
1000 patients with acute myocardial infarction who are
given one month of aspirin and then continue to take
low dose aspirin for some years, about 40 would avoid
a serious vascular event during the first month and
about a further 40 would avoid a vascular event in the
next couple of years. Similar sized long term benefits
are likely to be seen if antiplatelet therapy is started
soon after stroke or transient ischaemic attack and
continued long term. Even in patient populations at
intermediate risk (2›3% a year of serious occlusive vas›
cular events) such as some patients with no previous
vascular event but with stable angina, atrial fibrillation,
or peripheral arterial disease, antiplatelet therapy for a
couple of years would be expected to prevent about
10›15 vascular events for every 1000 patients treated.
The present evidence suggests that the propor›
tional increase in the risk of major bleeding of about
one half is similar among a wide range of categories of
patient. Population based observational studies have
found that regular use of aspirin (at a dose of <300
mg/day) is associated with around a twofold increased
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risk of upper gastrointestinal bleeding (or perfora›
tion).57 It therefore seems likely that the benefits of
antiplatelet therapy will far outweigh any hazards
unless the absolute risk of bleeding is high (such as
among haemodialysis patients) or the absolute risk of a
vascular event is low (as in apparently healthy people).
Consequently, unless some definite contraindication
exists, antiplatelet therapy should be considered
routinely for all patients whose medical history implies
a significant risk of occlusive vascular disease over the
next few months or years, and it should generally be
continued for as long as the risk remains high.
Potential for wider use of antiplatelet therapy in
high risk patients
Recent audits have shown that the use of antiplatelet
therapy has increased during the past few years but
that a substantial proportion of high risk patients still
do not receive it. For example, only about half (or less)
of all patients with a history of myocardial infarction,
angina, or peripheral arterial disease are currently
receiving antiplatelet therapy, and rates tend to be
lower in older people despite their higher absolute
risk.58–60 Use of aspirin among patients with diabetes is
even more limited, with one survey suggesting that less
than a quarter of those with a clear history of coronary
artery disease were taking regular aspirin,58 and
another study finding that only 7% of those without a
history of coronary artery disease were taking aspirin.60
Similarly, only about one third of patients with atrial
fibrillation receive oral anticoagulants, the most
effective treatment for the prevention of strokes in this
condition.61 62 This may be because of the associated
risks of bleeding and the need for anticoagulation
monitoring. But less than half of such patients who are
not taking anticoagulants receive antiplatelet therapy
despite the high risk of stroke (especially in elderly
people).63 64
These results reinforce the value of ensuring that
antiplatelet therapy with 75›150 mg aspirin daily (or
some other effective antiplatelet regimen) is consid›
ered routinely for all such patients at high or interme›
diate risk of occlusive vascular events (more than about
2% a year), irrespective of whether they have already
had a major vascular event. An unanswered question,
however, is whether it is possible to identify particular
groups of apparently healthy people who may be at
increased risk of myocardial infarction or stroke and
for whom the benefits of daily aspirin outweigh the
hazards. This is currently being investigated in an
analysis of primary prevention trials. For most healthy
individuals, however, for whom the risk of a vascular
event is likely to be substantially less than 1% a year,
daily aspirin may well be inappropriate.
This paper is dedicated to Gale Mead (1943›2001), who typed
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